Could a microRNA predict dangerous blood transfusion reactions?
NCT ID NCT07480980
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study will measure levels of a small molecule called microRNA-155 in 100 people who need regular blood transfusions, mostly due to beta thalassemia. The goal is to see if higher levels of this molecule are linked to the formation of harmful antibodies against donated blood. Researchers hope this knowledge can eventually help prevent serious transfusion complications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could point toward a way to predict or prevent dangerous immune reactions in people who need regular blood transfusions.
- What could go wrong
- This is an early observational study, not a treatment trial. It may not lead to any direct medical changes, and results may not apply to all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-THALASSEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease
- Mismatched donor stem cell transplant could widen treatment access for sickle cell disease
- How does a blood disorder drug perform in everyday practice?
- Newborn screening study aims to catch rare diseases at birth
- Old drugs, new hope: could a thalidomide combo free thalassemia patients from transfusions?
- Talking therapy could help thalassemia patients take their meds